CD274 and non-small cell lung carcinoma: However, biomarkers of the efficacy of immunotherapies are still lacking for many tumors, and there is large room for improvement for other tumor types where some biomarkers have shown a predictive value, such as PD-L1 expression and TMB in patients with non-small cell lung cancer (NSCLC) [5].